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Abstract 
Background: People who inject drugs (PWID) living with HIV often experience sub-optimal antiretroviral therapy 
(ART) treatment outcomes, including HIV plasma viral load (PVL) rebound. While previous studies have identified risk 
factors for PVL rebound among PWID, no study has examined the perspectives of PWID who have experienced PVL 
rebound episodes. We conducted an ethno-epidemiological study to investigate the circumstances surrounding the 
emergence of rebound episodes among PWID in Vancouver, BC, Canada.
Methods: Comprehensive clinical records linked to a community-based prospective observational cohort of HIV-
positive drug users were used to identify PWID who had recently experienced viral rebound. In-depth qualitative 
interviews with 16 male and 11 female participants explored participant perspectives regarding the emergence of 
viral rebound. A timeline depicting each participant’s HIV viral load and adherence to ART was used to elicit discussion 
of circumstances surrounding viral rebound.
Findings: Viral rebound episodes were shaped by interplay between various individual, social, and environmental 
factors that disrupted routines facilitating adherence. Structural-environmental influences resulting in non-adherence 
included housing transitions, changes in drug use patterns and intense drug scene involvement, and inadequate 
care for co-morbid health conditions. Social-environmental influences on ART adherence included poor interactions 
between care providers and patients producing non-adherence, and understandings of HIV treatment that fostered 
intentional treatment discontinuation.
Conclusions: This study describes key pathways which led to rebound episodes among PWID receiving ART and 
illustrates how environmental forces may increase vulnerability for non-adherence leading to treatment failure. Our 
findings have potential to help inform interventions and supports that address social-structural forces that foster non-
adherence among PWID.
Keywords: HIV, Injection drug use, Antiretroviral treatment, Treatment as prevention, Qualitative methods, Ethno-
epidemiology, Risk environment
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Background
Antiretroviral therapy (ART) inhibits HIV viral rep-
lication and suppresses HIV plasma viral load (PVL) 
to undetectable levels, resulting in reductions in HIV-
related morbidity and mortality, as well as reduced 
potential for onward HIV transmission [1]. Interven-
tions promoting the preventive benefit of ART to reduce 
the onward transmission of HIV, known as Treatment as 
Prevention (TasP), have become a cornerstone of global 
HIV prevention efforts [2]. Due to the high rates of HIV 
infection among people who inject drugs (PWID), this 
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population is a focus for TasP programs, but PWID often 
experience sub-optimal ART outcomes [3, 4], including 
high rates of treatment discontinuation and failure [5, 
6]. Poor treatment outcomes among PWID have poten-
tial to undermine the effectiveness of TasP in preventing 
injection-related HIV infections [7], and comprehensive 
efforts to promote viral suppression in this population 
are required [4, 8].
While contemporary perspectives on HIV treatment 
among PWID increasingly emphasize the role of social-
structural factors in shaping treatment outcomes [4], 
relatively few studies have investigated their impact 
on disease progression [9]. The HIV Risk Environment 
framework has been utilized to examine how HIV risk 
behaviours among PWID are shaped by interactions 
between individuals and social, structural, political, 
economic influences [10, 11], but has not yet been fully 
applied to examine the role various environmental forces 
play in shaping ART outcomes among PWID [9]. The 
Risk Environment framework has potential to help iden-
tify how broad social-level and structural-level influences 
constrain engagement with public health programs and 
impede individual ability to adhere to ART regimens [9–
11]. While some evidence suggests that socio-economic 
marginalization, HIV-related stigma and discrimination, 
the criminalization of drug use, incarceration, and inad-
equate access to substance use treatment [9, 11], pose 
barriers to adherence, less is known about how these 
forces function to produce sub-optimal ART outcomes. 
Similarly, although drug use has often been identified as 
a risk factor for suboptimal adherence among injection 
drug-using populations [12, 13], recent research has sug-
gested that PWID can achieve optimal adherence even 
in the context of ongoing drug use [14, 15]. This suggests 
that social-structural forces may play an important role 
in mediating the relationship between drug use and HIV 
treatment outcomes [9, 14, 15].
Plasma HIV-1 RNA viral load rebound (hereafter 
referred to as ‘rebound’), defined as the re-emergence of 
detectable plasma HIV viral load among individuals who 
had previously achieved viral suppression through ART, 
is a form of HIV treatment failure that represents a key 
challenge to the medical management of HIV [16, 17]. 
Approximately 10 % of all patients taking ART will expe-
rience a rebound episode [18], although it is not clear pre-
cisely how quickly viral load rebound emerge may due to 
missed doses of medication or treatment discontinuation 
given complex interactions between patient and virus 
characteristics, treatment histories, and regimen-specific 
effects. Shorter duration of viral suppression, particu-
lar ART medications, and non-adherence to treatment 
regimens are associated with increased risk of rebound, 
and viral rebound is a risk factor for the emergence of 
viral resistance, requiring less tolerable second-line and 
salvage-level therapies, and the onward transmission 
of transmission-resistant viruses [16, 18–20]. However, 
rebound appears to be far more common among PWID 
than other populations. A study from Vancouver, Canada, 
indicates that 45 % of PWID receiving ART displayed at 
least one rebound episode since initiating treatment [17]. 
In this study, rebound was associated with recent incar-
ceration and involvement in sex work, while methadone 
maintenance therapy (MMT) was negatively associated 
with rebound episodes [17]. Importantly, when analyses 
controlled for adherence to ART, no measure of drug use 
was found to predict the emergence of rebound [17].
Due to the importance of long-term retention on ART 
and prolonged viral suppression for the effectiveness of 
TasP, there is an urgent need for greater understanding of 
the emergence of virologic failure among PWID [8, 17]. 
While risk factors associated with rebound among PWID 
have been identified, research to date has not examined 
the perspectives of PWID displaying rebound or docu-
mented the circumstances surrounding rebound events. 
Detailed knowledge of the lived experience of drug users 
can generate understanding of the production of specific 
health outcomes, and to add a deeper social dimension 
to conventional quantitative measures [21, 22]. Integrat-
ing targeted qualitative research with epidemiological 
inquiry, known as ‘ethno-epidemiology’ [23–25], has 
potential to improve knowledge regarding ART treat-
ment outcomes by examining the experiences and per-
spectives of individuals who display particular outcomes. 
We conducted an ethno-epidemiological study to inves-
tigate the circumstances surrounding the emergence of 
rebound episodes among PWID in Vancouver, Canada, 
with a focus on the role of social-structural forces in the 
production of virologic failure. We examined the experi-
ences and perspectives of PWID who had a recent epi-
sode of rebound through targeted qualitative interviews.
Methods
This ethno-epidemiological study was nested within 
the AIDS Care Cohort to Evaluate Exposure to Survival 
Services (ACCESS), an ongoing prospective cohort of 
HIV-positive adults (≥18  years of age) with histories of 
illicit drug use (other than marijuana), which has been 
described previously [17]. Participants in this commu-
nity-recruited cohort study provide a blood sample for 
virologic analysis and complete an interviewer-admin-
istered behavioural questionnaire at baseline and every 
6  months thereafter. ACCESS data are linked with 
data collected by the Drug Treatment Programme of 
the British Columbia Centre for Excellence in HIV/
AIDS, a province-wide centralized ART dispensary and 
clinical monitoring laboratory, providing a complete 
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retrospective and prospective profile of CD4+ cell 
counts, PVL, and exposure to specific antiretroviral med-
ications for all participants [17]. Universal healthcare is 
provided in this setting, and all HIV care (including ART) 
is provided free of charge, permitting examination of 
treatment outcomes among PWID in a context without 
financial barriers to access or medications.
In April 2011, we conducted a database query to iden-
tify ACCESS participants with recent rebound experi-
ences. Inclusion criteria were all participants who: (i) 
were exposed to ART since enrolling in ACCESS; (ii) had 
at least two consecutive measurements indicating PVL 
suppression (<50 copies/mL) since 2007; and, had at least 
one measurement indicating elevated PVL (>1000 cop-
ies/mL) subsequent to PVL suppression. 43 individuals 
met these criteria, three of whom were recently deceased. 
For each participant, we generated a clinical timeline 
graphic (see Fig. 1) depicting PVL and adherence to ART 
over time. To estimate adherence, we used a validated 
measure based on pharmacy refill data [17], defined as 
the number of days ART was dispensed divided by the 
number of days since an individual was first dispensed 
therapy, capped at 180 days.
Potential participants were invited to participate in a 
qualitative interview when they visited or contacted the 
ACCESS cohort study office. Staff explained the study 
to potential participants and scheduled interviews. No 
one refused the offer to participate. We provided further 
information prior to the interview, and obtained writ-
ten informed consent. Interviews were conducted with 
twenty-seven participants (see demographics in Table 1) 
between May 2011 and May 2012. Twenty-four inter-
views were conducted by the lead author, while three 
were conducted by a PhD student trained in qualitative 
interviewing.
A semi-structured interview guide was used to facili-
tate discussion regarding the circumstances surrounding 
rebound episodes, including HIV care, ART dispensing 
arrangements, drug use, living circumstances, and other 
contextual factors. A modified format of timeline inter-
viewing, which is effective in linking individual narra-
tives and experiences to wider social and environmental 
contexts [26], was used to retrospectively examine HIV 
treatment experiences in relation to each participant’s 
drug use career and personal biography, as well as to 
situate their experiences within their social-structural 
contexts. A simple timeline was hand-drawn by the inter-
viewer during the interview, noting HIV care milestones 
and life events with the potential to impact upon ART 
adherence (e.g., housing transitions, changes in drug use 
Fig. 1 Sample clinical timeline graphic: detailing HIV plasma viral load and adherence over time for participant #12
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patterns). This approach elicited extensive discussion of 
social-structural influences shaping adherence, as well as 
transitions between periods of adherence and non-adher-
ence. The clinical timeline graphic was introduced at the 
conclusion of the interview to elicit further discussion of 
treatment events, summarize the interviewer’s interpreta-
tion of events, and allow participants to clarify inaccura-
cies. Some participants displayed more than one rebound 
episode over the study period, and all were examined 
during interviews and analysis. A total of 25 participants 
provided clear accounts of non-adherence related to their 
viral load rebound, as two participants were unable to 
provide a narrative regarding circumstances surrounding 
their rebound event due to problems related to recall.
Analysis focused on examining factors leading to pro-
longed interruption or discontinuation of ART. Interview 
transcripts and timelines were examined to understand 
each participant’s experience and rebound-related cir-
cumstances as an individual case, and a coding frame-
work composed of a priori and emergent codes (e.g., 
housing transitions, drug use transitions, social isolation, 
understandings of ART) was then used to compare and 
contrast these cases. We also drew on the Risk Environ-
ment framework in our analysis [11], as well as the con-
cept of structural vulnerability to illuminate how social 
and structural inequalities shaped engagement with 
care and adherence-related behaviour [27]. The analysis 
was conducted using word processing software to code, 
label, and retrieve data segments [28]. Ethics approval 
for the study was obtained from UBC/PHC Research 
Ethics Board. We have utilized the consolidated criteria 
for reporting qualitative research (COREQ) guidelines, 
to ensure full and accurate description of our study and 
analytical methods. [29] All names used in presenting the 
analysis are pseudonyms.
Results
Our findings illustrate how rebound episodes were 
shaped by the complex interplay between individual-level 
factors and social, structural, and environmental forces 
operating within the HIV treatment risk environment. 
Participants had previously achieved viral suppression by 
maintaining optimal ART adherence, and their accounts 
emphasized how they had managed or adjusted their 
living situations, HIV care, ART dispensing arrange-
ments, and drug use to ensure adherence through the 
development and maintenance of “stability” or regular 
“routines”. Rebound episodes were associated with dis-
ruption of these stable situations and routines, stemming 
from housing transitions, difficulty managing co-morbid 
health conditions, as well as changes in drug use and 
drug scene involvement. In addition, disruptions occur-
ring due to poor relationships with care providers and 
misunderstandings regarding ART resulted in intentional 
treatment discontinuation in several cases.
Impacts of housing transitions on ART dispensation 
and HIV care
For some participants, rebound episodes were temporally 
associated with changes in housing status and neighbour-
hood of residence, which negatively impacted HIV care. 
Housing transitions and neighbourhood relocations were 
particularly influential in disrupting established HIV 
care-related routines, and led to difficulty in re-estab-
lishing convenient ART dispensing arrangements. For 
example, Richard (participant #5, White Man, 52  years 
old) experienced a rebound episode after relocating to 
a neighbourhood approximately 5  km from where his 
HIV physician and pharmacy were located. He relied on 
a motorized wheelchair to travel to pick up his medica-
tions and his wheelchair began malfunctioning soon 
after moving. He was subsequently unable to pick up his 
HIV medications for more than 3  weeks, leading to his 
rebound episode.
HIV care and support services are concentrated in 
Vancouver’s urban core, and some participants experi-
enced reduced access to HIV care, ART medications, 
and related supports after relocating outside the down-
town core. Allen (participant #1, Afro-Canadian Man, 
51  years old) experienced a disruption to adherence 
when he moved from the downtown core to a rural area 
to undergo addiction treatment at a residential treat-
ment facility. He changed his pharmacy to pick up his 
monthly supply of ART medications closer to his new 
residence. Refilling his ART prescription required that 
he travel a considerable distance, and due to the lack of 
public transit and the regulations of the treatment facility 
he was attending, it was sometimes not possible to pick 
up his ART prescription until weeks after his supply of 
medication was exhausted. Difficulty picking up his ART 
medications resulted in non-adherence, which led to his 
rebound episode. Similar dynamics were evident in the 
experience of Bernadette (participant #10, Aboriginal 
Table 1 Characteristics of study participants
Characteristics Interview participants n 
(%); n = 27
Age
 Median (min–max) 46.7 (32–54)
Gender
 Women 11 (40.74)
 Men 16 (59.25)
Aboriginal ancestry
 Yes 11 (40.74)
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Woman, 45  years old), who lived in a supported living 
residence for HIV positive individuals (including on-site 
ART dispensation), during the time she displayed viral 
suppression. Her rebound episode emerged soon after 
she relocated to a small town outside the city with her 
boyfriend. This change in residence reduced her access 
to HIV care and ART-related supports (e.g., daily dis-
pensing), which previously facilitated optimal adherence, 
leading to non-adherence and, subsequently, her rebound 
episode. These accounts illustrate the interplay between 
location of residence and ART dispensing arrangements, 
and how disruptions associated with relocations can 
result in prolonged non-adherence and rebound.
Relationships between extreme poverty, drug use, 
and non‑adherence to ART
Regular ongoing illicit drug use was not reported to 
impede adherence, as many participants maintained 
viral suppression while continuing to use drugs. How-
ever, significant changes in drug use patterns were 
reported to hinder ability to take medications as pre-
scribed in the context of extreme poverty and con-
strained opportunities for legal income generation. 
Participant accounts emphasized how increases in drug 
use, including episodes of binge use (often following 
the monthly distribution of social assistance benefits) 
and intense drug scene participation resulted in non-
adherence leading to rebound episodes. Intense drug 
scene involvement was a key mechanism producing non-
adherence, as participants reported that spending large 
amounts of time generating income (e.g., dealing drugs), 
and obtaining and using drugs disrupted adherence-
related routines by keeping them away from home and 
their ART medication supply. The impact of these dis-
ruptions were exacerbated by various social, structural 
and environmental conditions related to the local drug 
scene, including difficulties generating income, the high 
costs of drugs within an unregulated market, and severe 
isolation due to a lack of social interactions outside the 
drug scene. Barriers to managing drug dependency were 
also evident in participant accounts and related to the 
impacts of changes in drug use patterns on adherence, 
including negative perceptions of regulations associated 
with MMT programs (e.g., observed daily dosing) and 
the lack of effective pharmacotherapies for stimulant 
use.
A recurring pattern of drug use binges was cited as 
playing a key role in producing multiple rebound epi-
sodes for Dan (participant #16, White Man, 48  years 
old), who described sustained binges that would result in 
multiple weeks of non-adherence. During periods of viral 
suppression, he reported using drugs in a more moder-
ate manner. Episodes of binge drug use had a profound 
effect on his adherence due to the time and energy spent 
obtaining and using drugs. He attributed each of the 
rebound episodes in his clinical profile to prolonged drug 
binges:
I went off it [ART] again cause I went on more on 
[street] drugs […] Each time where I’ve [lost suppres-
sion]… I’ve gone off on a binge.
For other participants, intense drug scene involvement 
and the time spent generating income illegally and using 
drugs was perceived to negatively impact adherence due 
to the disruption of regular routines and time spent away 
from home and supplies of ART medications. Brendan 
(participant #2, White Man, 41  years old) reported 
spending large amounts of time in the drug scene to 
make money to purchase drugs, and then, after using 
stimulants for a prolonged period (often days), he would 
take a sleeping pill to “crash”. This resulted in numerous 
days each month when he would miss taking his ART due 
to the disruption of his normal routine (often coincid-
ing with the payment of social assistance benefits). Simi-
larly, Don (participant #21, White Man, 48  years old), 
described how his rebound episode emerged during a 
time when intense drug scene involvement resulted in an 
unstable lifestyle, which he contrasted with his stability 
and routines during periods of viral suppression. Insta-
bility stemming from drug scene involvement including 
illegal income generation (e.g., shoplifting), homelessness 
and repeated arrests and detentions, and difficulty man-
aging drug dependency precipitated his rebound episode:
I’ve always took my meds [ART], but for a few 
months there I was a little fucked up […] I wasn’t 
taking them [ART] responsibly. [I was] stopping and 
starting …[due to] the erratic lifestyle of like being 
homeless.
While his adherence was briefly disrupted when incar-
cerated, he attributed his rebound episode primarily to 
the interaction of factors stemming from the instability of 
being homeless and entrenched in the drug scene.
Inadequate care and support for comorbid conditions
Among participants with complex co-morbidities (e.g., 
mental health issues, chronic pain, opioid dependency), 
difficulties managing these conditions due to inadequate 
care and support led to disruptions in their regular rou-
tine and ART adherence, which contributed to rebound 
episodes. For Dave (participant #24, White Man, 49 years 
old), pain and reduced mobility shaped non-adherence 
by limiting his ability to pick up ART medications for 
self-administration. He experienced intense chronic 
pain from a spinal injury, and reported that his pain 
management was often inadequate. He had previously 
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been prescribed morphine, which effectively managed 
his pain, but his physician had become reluctant to con-
tinue to provide this medication due to strict prescribing 
guidelines for opioid analgesics imposed by local medical 
regulatory body. Prior to his rebound episode, the pain 
from his spinal injury was unmanaged due to the discon-
tinuation of his morphine prescription, which made it 
difficult for him to walk and, therefore, travel to his phar-
macy to refill his ART prescription. Dave subsequently 
experienced a period of ART non-adherence lasting more 
than a month.
Inadequate care for ongoing and emergent mental 
health conditions was also critical in shaping non-adher-
ence and rebound episodes. For example, Mary (partici-
pant #3, Aboriginal Woman, 37 years old) described how 
non-adherence to medications prescribed for her bipolar 
disorder often interfered with adherence to ART. Her 
rebound episode occurred when she was not taking both 
her “psych meds” and ART medications for a prolonged 
period because she felt depressed and suicidal. She 
reported that mental health services in the community 
did not provide her with adequate support, and she had 
to be hospitalised to receive care for her bipolar disor-
der. Meanwhile, because most participants were socially 
isolated, difficult life events (e.g., child apprehension, 
death of a family member) often led to serious depres-
sion accompanied by increased drug use, ART treat-
ment interruptions, and rebound episodes. For example, 
Donna (participant #7, Aboriginal Woman, 35  years 
old) was forced to give up her baby to foster care soon 
after he was born, which led to deep depression, result-
ing in increased drug use and non-adherence to ART 
medications:
I gave him [her son] up [to foster care]. I went onto 
the streets and started using heavy and got sick 
[depressed]…And stopped taking my meds [ART].
Although she was engaged with services related to the 
foster care system, as well as HIV-related care, she did not 
receive adequate care for her depression, and self-medi-
cated with illicit drugs. Similar dynamics were evident in 
the experiences of four other participants who reported 
that the death of family member resulted in depres-
sion accompanied by increased drug use. This relatively 
common sequence of events illustrates how interaction 
between life events, mental health issues, and changing 
drug use patterns precipitated rebound episodes among 
structurally vulnerable PWID who lacked mental health 
supports and strong support networks.
Difficulty managing opioid dependence, partially due 
to strict rules governing methadone therapy, resulted in 
MMT discontinuation and ART non-adherence for one 
participant. During the time that Laurie (participant #20, 
Aboriginal Woman, 38 years old) displayed viral suppres-
sion, she was receiving take away doses of methadone 
(“carries”) and daily-observed ART through her phar-
macy. She reported being “cut-off” MMT carries when 
it was discovered that she was injecting her methadone 
and, since she was opposed to daily-observed methadone 
dispensation, she discontinued MMT. She subsequently 
began using large amounts of heroin and diverted metha-
done to manage her opiate dependence, and selling drugs 
to generate income. Managing opioid dependence by 
using illicit opioids rather than receiving MMT reduced 
her motivation to visit the pharmacy to pick up ART 
medications, resulting in non-adherence and rebound.
Provider‑patient interactions related to ART
Poor communication and interactions with HIV care 
providers negatively impacted individual adherence, and 
resulted in non-adherence and intentional treatment dis-
continuation among several participants. Calvin (par-
ticipant #18, White Man, 55 years old) described how an 
intense disagreement with his physician led him to discon-
tinue both ART treatment and MMT, which subsequently 
resulted in an episode of viral rebound. His physician 
expressed concerns regarding his adherence based upon 
reports from support staff at his residence stating that he 
had not been picking up his medications. He explained 
to his physician he had indeed been taking ART as pre-
scribed, and that he had a stockpile of medications because 
he had not started his ART regimen until a month after 
receiving his first prescription. His physician demanded 
that he receive maximally assisted treatment/directly 
observed therapy (MAT/DOT) to address the perceived 
problem with adherence. He was vehemently opposed to 
observed therapy because he felt he was capable of being 
adherent and taking his medication independently:
Calvin: I explained to her what I was doing [adhering 
to regimen as prescribed by taking stockpiled medica-
tions], right… and she didn’t want to hear me. So, I 
ended up being off the medication [ART] and I got off 
methadone…
Interviewer: So she really wanted then for you to go 
every day and take the observed maximally assisted 
therapy?
Calvin: Exactly! I wasn’t gonna do that, no… Not at 
my age… I was over fifty years old. I know what I’m 
doing.
The conflict with his physician caused him to leave 
care and discontinue ART treatment and MMT. He did 
not re-initiate ART until 24 months after this discontin-
uation event and remained off MMT for approximately 
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6 months, during which time he used heroin to manage 
his opioid dependence.
Similarly, Shelley (participant #26, Aboriginal Woman, 
43  years old) described how she “rebelled” against her 
physician’s decision to put her onto MAT/DOT against 
her wishes by not adhering to her ART medication. She 
positioned observed therapy as paternalistic, empha-
sizing that she was “not a kid” and was indeed able to 
adhere to her regimen. She actively resisted her physi-
cian’s decision by not attending the MAT/DOT pro-
gram to take her ART medications, which resulted in 
her rebound episode. These cases illustrate the impact 
of physicians’ decisions to have PWID patients receive 
directly observed therapy against their wishes, which 
unintentionally led to non-adherence and rebound 
because participants felt such arrangements were too 
paternalistic.
Negative interactions with care providers were also 
influential in the case of Marianne (participant #27, Abo-
riginal Woman, 41 years old), who was non-adherent for 
3 months while incarcerated. Her ART medications were 
not available until 3 weeks after she arrived at a correc-
tional facility. However, due to her frustration with the 
inability of institutional health care services to provide 
her medications, she refused to take her ART, despite 
awareness of the negative impact that this would have on 
her HIV treatment. She did not reinitiate ART until she 
was released to the community, and the 3 months of non-
adherence while in correctional custody resulted in her 
rebound episode:
I didn’t take it [ART]. I did [served] three months 
and then when I got out, I started taking it again.
While the problems experienced by this participant 
partially stemmed from a lack of continuity in HIV care 
when in correctional custody, she reported that poor 
relationships institutional healthcare providers also led 
to her decision to intentionally discontinue her ART until 
she was released from jail.
Local understandings of ART
Social influences and popular understandings of ART 
influenced participants’ beliefs regarding ART and, in 
turn, their adherence. Misunderstandings regarding 
adherence, management of ART resistance, and disease 
progression precipitated non-adherence to ART, as well 
as instances where patients intentionally discontinued 
their ART treatment. For example, Malcolm (participant 
#23, White Man, 49 years old) reported how ambivalence 
towards HIV treatment fostered his non-adherence, 
partially due to the understanding that intense drug use 
and ART were not compatible. During a period when he 
was using illicit drugs heavily, he reported low levels of 
motivation to adhere to ART medications as prescribed 
and experienced a rebound episode:
You know when you’re not really into it [ART treat-
ment], you don’t [take your medications]. I was still 
skipping doses and all that. I wasn’t really honest 
with myself […] I’d take them just when I thought I’d 
have to. Right? I had drawer full [of ART doses he 
had not taken] Fuck the medication. […] I was using 
fucking almost a half a eight ball [1.75 grams] of her-
oin a day.
In a number of cases, patients intentionally discontin-
ued their treatment despite awareness that they displayed 
undetectable viral load measures. Brett (participant #4, 
White Man, 53  years old) discontinued his ART inten-
tionally due to concerns regarding missed doses, misun-
derstandings regarding ART resistance, and out-dated 
ideas regarding best practices in HIV treatment. He 
enacted a self-imposed treatment interruption because 
he believed stopping treatment would eliminate the 
potential for ART resistance and extend the effectiveness 
of his current ART regimen:
I was on a structured treatment interruption- my 
own. I had missed enough adherence [doses] so… I 
went off for a year. And the doctor said why? I said… 
Instead of building a tolerance [resistance] it’s better 
if I go off it till I got no tolerance, and then we can 
put me back on it. So I did my own structured, my 
own treatment interruption.
Similarly, Eric (participant #12, White Man, 53  years 
old) believed a treatment interruption might be a good 
way to prolong the efficacy of his current regimen, as 
he had begun ART treatment 19  years earlier and was 
concerned about long-term use of ART. His decision to 
discontinue ART, undertaken without consultation with 
his physician, was partially due to encountering informa-
tion regarding strategic treatment interruptions in an old 
copy of a newsletter for HIV-positive individuals:
I thought that a drug holiday would help. So I took 
myself off [ART] for one year and then…the viral 
load jumped up I took myself back on […] After more 
study they realized that it’s not good, but by that 
time I was already off of it so…
This participant’s decision to discontinue treatment 
was partially shaped by his experiences with early treat-
ment regimens, which influenced his understanding of 
contemporary therapeutic approaches. These intentional 
discontinuations occurred after structured treatment 
interruptions were no longer deemed clinically beneficial, 
and individual decisions to stop ART medications were 
not supported by physicians.
Page 8 of 12Small et al. AIDS Res Ther  (2016) 13:26 
A lack of recognition that managing HIV with ART 
requires lifelong adherence to daily medication regimens 
reduced willingness to continue ART among some par-
ticipants, leading to intentional treatment discontinua-
tion. Darla (participant #9, White Woman, 56 years old) 
described her decision to discontinue ART, emphasis-
ing that taking numerous pills every day for years had 
become unappealing despite awareness that she had 
achieved viral suppression:
I was undetectable for about two or three years. I 
just got tired of taking so many pills every day […]
my viral load was right down and so I just said “I’m 
taking a break. I’m not gonna take it [ART] any-
more. I’m just on too many pills.” […] It was some-
thing I just wanted to do and just kind of feel normal 
if I don’t have to take these pills every morning when 
I get up and again at night […] I just get sick of tak-
ing them.
Similarly, Elaine (participant #15, White Woman, 
50 years old) discontinued treatment when her viral load 
was undetectable, partially due to the belief that the posi-
tive outcomes she was experiencing (e.g., sense of well-
being, weight gain) meant that she no longer needed to 
take ART to manage her HIV:
I just got frustrated with taking them every day […] 
I started gaining weight and I started feeling good. 
I thought… “now I can do it on my own. Maybe I 
didn’t need it [ART].” I just wanted to try to see if 
I can [live without medication]. But right away I 
started to crash, and I need the meds. I thought I 
was doing so good that I probably didn’t [need medi-
cation], I probably could do it on my own- I didn’t 
really need these pills anymore. And it’s not so, cause 
my body needs them… obviously.
Discussion
The findings of our study illustrate the role of interac-
tions between individual-level factors and diverse social-
structural forces operating within the HIV treatment risk 
environment in shaping the emergence of rebound epi-
sodes among PWID. Rebound episodes emerged when 
routines that facilitated adherence were disrupted by 
structural-environmental influences, including housing 
transitions, changes in drug use patterns and drug scene 
involvement, and inadequate care for comorbid health 
conditions. Social-environmental influences similarly 
disrupted participants’ adherence to ART as poor com-
munication between care providers and patients pre-
cipitated non-adherence, and misunderstandings of ART 
functioned to reduce motivation to adhere to ART and 
produced intentional treatment discontinuation.
This study is the first to use qualitative and ethno-
epidemiological methods to examine viral load rebound 
among PWID. Our findings generate new knowledge 
regarding how structural-environmental and social-envi-
ronmental forces influence ART non-adherence among 
PWID, and lead to rebound episodes. While being home-
less or marginally housed is a known risk factor for poor 
ART adherence and treatment outcomes among PWID 
[9, 30, 31], our findings indicate that housing transitions, 
including relocating to a different neighborhood, may 
influence treatment outcomes even among HIV-positive 
PWID who are continuously housed. These dynam-
ics suggest that transitions in housing and relocation to 
different neighborhoods may be particularly influential 
among structurally vulnerable PWID, as living and care 
arrangements that function to enable optimal adher-
ence may be easily disrupted. Changes in housing status 
and residence may also play a role in driving increases in 
drug use and involvement in illegal income generation 
among drug users [32], further underscoring the impor-
tance of maintaining housing stability among HIV posi-
tive PWID. Interventions designed to improve housing 
stability and quality may reduce the potential for non-
adherence [33], but efforts to improve continuity of HIV 
care for individuals relocating their residence should 
focus upon ensuring specialist care and appropriate dis-
pensing arrangements subsequent to housing transitions. 
Importantly, both supportive housing models and hous-
ing utilizing harm reduction supports appear to facilitate 
adherence among PWID given the documented benefi-
cial effect on viral load [30, 34].
Recent research has challenged the perspective that 
illicit drug use directly contributes to poor ART out-
comes [9], highlighting the importance of ART adher-
ence in mediating the relationship between drug use and 
treatment outcomes [14, 15]. Our results underscore the 
importance of understanding how extra-individual forces 
(including physical and psychological comorbidities) 
interact with varying patterns of drug use to shape non-
adherence [9], and elucidate how changes in drug use 
and drug scene involvement impede individual ability to 
adhere by disrupting adherence-related routines. Intense 
drug scene exposure has previously been associated with 
poor health outcomes and more severe substance use 
[35], and our findings suggest that time spent in the drug 
scene (generating income and using drugs) represents a 
mechanism through which drug use shapes non-adher-
ence. Given that intensity of drug scene involvement and 
illegal income generation may mediate the relationship 
between drug use and ART adherence, the potential of 
alternative income generation and low-threshold employ-
ment interventions for PWID living with HIV should be 
explored [36, 37]. Improving economic opportunities 
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may represent an effective strategy to reduce or limit 
drug use and drug scene involvement [32], and employ-
ment has been previously documented to positively 
impact ART adherence [38].
While MMT has been associated with optimal adher-
ence [39–41], our findings illustrate how the benefit of 
MMT upon ART adherence can be eroded and negated 
among PWID. Specifically, we found that MMT dis-
continuation events also coincided with non-adherence 
and viral rebound. An established literature shows that 
restrictive programmatic features of MMT can result in 
suboptimal outcomes and poor treatment retention [42, 
43], and additional supports for HIV-positive PWID 
should be considered, including low threshold MMT, 
outreach to individuals who discontinue MMT, and alter-
natives to MMT (including heroin prescription programs 
and buprenorphine). These supports might help facilitate 
optimal adherence over the long-term among PWID.
Inadequate support across the continuum of care for 
PWID living with HIV with comorbid conditions (e.g., 
mental health conditions) resulted in non-adherence and 
rebound. While it is recognized that medical and psy-
chiatric comorbidities among HIV-positive PWID (and 
the concurrent nature of these conditions) contribute 
to poor ART outcomes [44], appropriate interventions 
are lacking in most settings. The role comorbid condi-
tions played in disrupting adherence among study par-
ticipants illustrates the importance of comprehensive 
care and support for HIV positive PWID in maintaining 
optimal adherence. There is a need for integrated health 
services, including multi-component and interdiscipli-
nary approaches, delivering integrated case management 
to simultaneously improve the management of comorbid 
conditions and adherence to ART [44–47].
In the context of inadequate linkage with mental health 
services, existing and emergent mental health condi-
tions affected adherence, illustrating the importance of 
enhanced care and support for mental health conditions 
among HIV-positive PWID. Interventions to manage 
mental health conditions among PWID include commu-
nity-based integrated mental health services programs, 
social supports, peer-support programs, and housing-
based interventions [48, 49]. Unfortunately, in many 
settings (including Vancouver), biomedical and legal 
approaches to the management of mental illness have 
become increasingly dominant, detracting attention from 
social and structural forces driving suboptimal treatment 
of mental health conditions, and eroding support for 
community-based programs [48]. Detainment of indi-
viduals diagnosed with mental illness produces negative 
effects on adherence and treatment outcomes [4]. The 
utilization of peer-based interventions [50, 51], includ-
ing peer-counselling, peer navigators, and peer-support 
programs, could contribute to the effective management 
of mental illness and simultaneously support optimal 
adherence among PWID [52–54]. Local drug user groups 
may be a vehicle for mobilizing community resources to 
promote social support and engagement with care [55].
Our findings also indicate that poor communication 
and interactions between care providers and patients 
precipitated discontinuation of ART, particularly in 
relation to physician decisions regarding the necessity 
of MAT/DOT programs to ensure adherence among 
PWID. While MAT/DOT programs are associated with 
improved adherence and increased likelihood of viral 
suppression [56], treatment decisions should be jointly 
made by patients and physicians [57], and with the 
understanding that some participants perceive observed 
therapy to be paternalistic. While our findings are con-
sistent with past work showing that incarceration may 
shape non-adherence through treatment interruptions 
stemming from delays in obtaining medications while 
in custody [6, 58], poor relationships with institutional 
health care providers may also lead PWID to discon-
tinue ART while incarcerated. These dynamics have 
previously been documented in our setting [59], and 
PWID routinely re-initiate treatment upon return to the 
community, although some do experience challenges 
obtaining medications and connecting with physicians 
post-release. As noted previously, correctional services 
have a duty to provide essential health care in a timely 
manner, including ART medications, and such efforts are 
essential to ensuring continuity of HIV care for PWID 
who experience incarceration [59]. Improving relation-
ships and communication between PWID and physi-
cians may benefit adherence [60], and efforts to improve 
patient-provider interactions may involve better training 
for physicians who care for PWID, as well as education 
regarding addiction medicine and substitution therapies 
for opioid dependence [61, 62].
Understandings of HIV treatment played a role in shap-
ing adherence to ART among study participants. Our 
findings illustrate how numerous years of ART may accu-
mulate to make individuals “tired” of pills given a lack of 
appreciation that managing HIV with ART requires life-
long adherence. This illustrates how treatment fatigue 
plays a role in shaping intentional treatment discontinu-
ation, as qualitative examination of these issues has been 
lacking to date [63]. While increasingly simple regimens 
involving fewer pills may reduce levels of fatigue, ensur-
ing long-term retention of PWID will require further 
interventions to prevent intentional discontinuation 
and that care providers emphasize the lifelong nature of 
ART when communicating with patients [64]. In addi-
tion, individuals may want to have a sense of control over 
their HIV treatment and medications, which may entail 
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stopping or modifying treatment regimens (particularly 
in the context of long-term ART), and these dynamics 
may further complicate communication between patients 
and care providers. Our findings document how particu-
lar beliefs regarding resistance and disease progression, 
as well as anachronistic ideas regarding best practices 
in HIV treatment, played a role in producing intentional 
treatment discontinuation. This is particularly signifi-
cant given emerging clinical research suggesting that 
rates of antiretroviral resistance among PWID are less of 
a concern than previously thought [65], highlighting the 
importance of care providers delivering ongoing educa-
tion and accurate information about HIV treatment [66]. 
While improving patient-provider communication is an 
important strategy for correcting misconceptions regard-
ing ART, social models of education and information 
provision (similar to peer-led safer injection education) 
might also improve understandings of ART [55], correct 
outdated beliefs, and address common concerns regard-
ing long term retention in HIV treatment [67].
The current study has several limitations. Our findings 
are specific to the experience of individuals participating 
in the study, and other PWID displaying viral rebound 
may have different experiences and perspectives. Some 
participants were not able to describe circumstances 
surrounding the emergence of rebound episodes, and 
our analysis has placed emphasis upon cases where par-
ticipants were able to provide a complete account of the 
emergence of rebound episodes. While the design of 
our study allowed for direct examination of the experi-
ences of PWID who recently displayed rebound, further 
research regarding circumstances surrounding rebound 
is needed.
Conclusions
In conclusion, this study identified pathways leading to 
viral rebound episodes among PWID who had achieved 
viral suppression, and illustrates the impact of environ-
mental forces in shaping non-adherence and treatment 
failure. Our findings highlight the need for interventions 
and supports that address the social-structural forces 
that create vulnerability to ART non-adherence among 
PWID.
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